Analytical Data
-
Gene name
CCNB
- Application
-
Alternative Names
CCNB1; CCN-B; G2/Mitotic-Specific Cyclin B1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14635
-
Expression Region
Val239~Val433
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNB, or Cyclin B, is a critical regulatory protein involved in the control of the cell cycle, particularly during the transition from G2 phase to mitosis. Research into CCNB and its associated pathways has gained prominence due to its essential role in cellular proliferation and its implications in cancer biology. The dysregulation of CCNB expression or activity has been linked to various malignancies, making it a target for therapeutic interventions. Moreover, CCNB is known to form complexes with Cyclin-dependent kinases (CDKs), facilitating the phosphorylation of key substrates that drive mitotic entry. Recent studies have focused on the structural and functional characterization of CCNB as a recombinant protein to better understand its interaction with CDKs and other regulatory molecules. This research aims to elucidate the mechanisms by which CCNB contributes to cell cycle progression and to identify potential pharmaceutical targets for cancer treatment. By producing CCNB as a recombinant protein, scientists can perform in vitro assays to study its biochemical properties, interactions, and potential inhibitors, paving the way for novel therapeutic strategies aimed at regulating cell division in cancerous cells. The insights gained from these studies may not only enhance our understanding of cell cycle regulation but also contribute to the development of targeted therapies that can improve patient outcomes in oncological settings.
